Bristol-Myers Squibb Co. (BMY)

60.89
NYSE : Health Technology
Prev Close 61.11
Day Low/High 60.80 / 61.59
52 Wk Low/High 49.96 / 70.05
Avg Volume 6.30M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 99.72B
EPS 0.60
P/E Ratio 254.62
Div & Yield 1.60 (2.64%)
FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Bristol-Myers Squibb Company To Contact The Firm

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Bristol-Myers Squibb Company To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf...

Women's History Month: Nancy Lieberman -- Still Law Firm's Youngest Partner Ever

Women's History Month: Nancy Lieberman -- Still Law Firm's Youngest Partner Ever

For Women's History Month, Alpha Rising sat down with Nancy Lieberman, Of Counsel at Skadden, Arps. She was and still is the youngest person to ever make partner at her firm. She has worked on some of the biggest M&A deals in history -- and we should mention -- she's in a wheelchair and barely as use of her hands. Feel like a slacker yet? Good. Watch.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Bristol-Myers Squibb Company Of Class Action Lawsuit And Upcoming Deadline - BMY

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Bristol-Myers Squibb Company Of Class Action Lawsuit And Upcoming Deadline - BMY

Pomerantz LLP announces that a class action lawsuit has been filed against Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company") (NYSE:BMY) and certain of its officers.

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo Four-Week Dosing Schedule For Advanced Melanoma And Previously Treated Renal Cell Carcinoma

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo Four-Week Dosing Schedule For Advanced Melanoma And Previously Treated Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of an every four-week (Q4W) Opdivo...

Bristol-Myers Squibb Could Trade Sideways Till the Bull Returns

Bristol-Myers Squibb Could Trade Sideways Till the Bull Returns

Let's check out the charts and indicators for some guidance.

53 Value Stocks That the Federal Reserve May Make Unbeatable Buys

53 Value Stocks That the Federal Reserve May Make Unbeatable Buys

Value stocks haven't done well in the era of easy money, with cash piling into growth names. But, that could be about to change.

BMY LOSS NOTICE: Rosen Law Firm Reminds Bristol-Myers Squibb Company Investors Of Important April 10, 2018 Deadline In Class Action - BMY

BMY LOSS NOTICE: Rosen Law Firm Reminds Bristol-Myers Squibb Company Investors Of Important April 10, 2018 Deadline In Class Action - BMY

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Bristol-Myers Squibb Company (NYSE: BMY) from January 27, 2015 through October 9, 2016, inclusive (the "Class Period") of the...

Pfizer CEO Ian Read Gets 61% Raise to Keep Him From Considering Retirement

Pfizer CEO Ian Read Gets 61% Raise to Keep Him From Considering Retirement

Pfizer's CEO Ian Read could make almost $28 million in the next year to keep him from retiring. Strangely enough, he may earn it given the healthcare and political environment.

Research From Bristol-Myers Squibb's Innovative Oncology Development Program To Be Presented At AACR 2018 Demonstrates Commitment To Advancing Precision Medicine Research For Patients With Cancer

Research From Bristol-Myers Squibb's Innovative Oncology Development Program To Be Presented At AACR 2018 Demonstrates Commitment To Advancing Precision Medicine Research For Patients With Cancer

Bristol-Myers Squibb Company (NYSE:BMY) today announced the presentation of new data showcasing advances in the science of Immuno-Oncology at the American Association for Cancer Research (AACR) Annual Meeting in...

Bristol-Myers Squibb To Announce Results For First Quarter 2018 On April 26

Bristol-Myers Squibb To Announce Results For First Quarter 2018 On April 26

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2018 on Thursday, April 26, 2018.

The Klein Law Firm Reminds Investors Of A Class Action On Behalf Of Bristol-Myers Squibb Company Shareholders And A Lead Plaintiff Deadline Of April 10, 2018 (BMY)

The Klein Law Firm Reminds Investors Of A Class Action On Behalf Of Bristol-Myers Squibb Company Shareholders And A Lead Plaintiff Deadline Of April 10, 2018 (BMY)

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Bristol-Myers Squibb Company (NYSE:BMY) who purchased shares between January 27, 2015 and October 9, 2016.

The Klein Law Firm Reminds Investors Of A Class Action On Behalf Of Bristol-Myers Squibb Company Shareholders And A Lead Plaintiff Deadline Of April 10, 2018

The Klein Law Firm Reminds Investors Of A Class Action On Behalf Of Bristol-Myers Squibb Company Shareholders And A Lead Plaintiff Deadline Of April 10, 2018

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Bristol-Myers Squibb Company (NYSE: BMY) who purchased shares between January 27, 2015 and October 9, 2016.

Jim Cramer: Will the Techs Be Challenged, Too?

Jim Cramer: Will the Techs Be Challenged, Too?

The theft of intellectual property can be confronted by a Section 301 challenge directly from the trade representative.

BMY INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Bristol-Myers Squibb Company And A Lead Plaintiff Deadline Of April 10, 2018

BMY INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Bristol-Myers Squibb Company And A Lead Plaintiff Deadline Of April 10, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who purchased Bristol-Myers Squibb...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CZR, ERII, IGT Downgrades: AAME, ANW, AVDL, BMY, COO, EGOV, MEET, MRVL, PCMI, VTR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Bristol-Myers Squibb Company Of A Class Action And A Lead Plaintiff Deadline Of April 10, 2018

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Bristol-Myers Squibb Company Of A Class Action And A Lead Plaintiff Deadline Of April 10, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Bristol-Myers Squibb Company ("Bristol-Myers") (NYSE:BMY)...

Bristol-Myers Squibb To Take Part In Barclays Global Healthcare Conference

Bristol-Myers Squibb To Take Part In Barclays Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will present at Barclays Global Healthcare Conference on Wednesday, March 14, 2018, in Miami.

The Klein Law Firm Announces Commencement Of A Class Action On Behalf Of Bristol-Myers Squibb Company Shareholders And A Lead Plaintiff Deadline Of April 10, 2018 (BMY)

The Klein Law Firm Announces Commencement Of A Class Action On Behalf Of Bristol-Myers Squibb Company Shareholders And A Lead Plaintiff Deadline Of April 10, 2018 (BMY)

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Bristol-Myers Squibb Company (NYSE:BMY) who purchased shares between January 27, 2015 and October 9, 2016.

Bristol-Myers Squibb's Opdivo® (nivolumab) Now The First And Only FDA-Approved PD-1 Inhibitor To Offer Every Four-Week Dosing

Bristol-Myers Squibb's Opdivo® (nivolumab) Now The First And Only FDA-Approved PD-1 Inhibitor To Offer Every Four-Week Dosing

Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.

10 Stocks Investors Raced to Buy During February's Brutal Market Correction

10 Stocks Investors Raced to Buy During February's Brutal Market Correction

Sensing an opportunity, investors raced to eat up several big-cap stocks in February. Here are the biggest buys.

Bristol-Myers Squibb To Take Part In Cowen And Company 38th Annual Global Health Care Conference

Bristol-Myers Squibb To Take Part In Cowen And Company 38th Annual Global Health Care Conference

Bristol-Myers Squibb Company (NYSE:BMY) will participate in the Cowen and Company 38 th Annual Global Health Care Conference on Monday, March 12, 2018, in Boston.

Square, Manitowoc, FMC Corp: 'Mad Money' Lightning Round

Square, Manitowoc, FMC Corp: 'Mad Money' Lightning Round

Jim Cramer takes a look at Square, Manitowoc, Valley National Bancorp, FMC Corp., Universal Display, CIT Group, Oneok, and Albemarle.

Jim Cramer: Here's 10 Things to Watch For

Jim Cramer: Here's 10 Things to Watch For

You just have to look at it like a drill.

TheStreet Quant Rating: C+ (Hold)